Aim: People with dementia commonly live with multiple comorbidities. This review aimed to review medications to manage chronic conditions in people who also have a diagnosis of dementia. The secondary aim was to determine whether drug utilisation for other conditions change as a result of dementia diagnosis. Methods: Data source: We included experimental and observational studies where participants with dementia were diagnosed and treated for one or more comorbid conditions that reported health outcomes or drug utilisation. Study selection: MedLine and Embase databases were searched from inception to March 2016 (updated September 2016). Three researchers screened titles, abstracts and full-text articles, then extracted data using a data extraction sheet. Results: Six studies met inclusion criteria with 51 696 participants (mean age 81.1 AE 2.0 years, 78% female). One experimental study compared bisphosphonate use with placebo in people with mid-stage dementia and found reduced risk of non-vertebral fractures (OR = 0.27, 95% CI 0.12-0.61) in the bisphosphonate group. Five observational studies reported drug utilisation for people with dementia to treat comorbidities, namely depression, osteoporosis, diabetes and cardiovascular disease. Drug utilisation was found to be similar for depression, diabetes and cardiovascular disease for people with and without dementia, although bisphosphonate use was significantly reduced. Conclusion: Evidence on medication use for comorbidities in people with dementia is currently limited to drug utilisation patterns and treatment of one comorbidity: osteoporosis. Comorbidities for people with dementia appear to be managed pharmacologically until the late stages of disease without considering time to benefit or that it is a life-limiting condition.
INTRODUCTION
Older age is a risk factor for many chronic conditions and as such many older people live with multiple chronic morbidities. 1 These chronic conditions are often managed with medications that aim to control disease progression or to prevent a future serious event. 2 Alternatively, conditions can be managed with medications to provide symptomatic relief. As such, optimal medication management for older people aims to improve health outcomes.
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Dementia is one such chronic condition that is strongly associated with older age. 4 One in 25 people have a diagnosis of dementia by age 65 years, but this rises to one in four people by age 80 years. 5 Dementia can be defined as the 'significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition)' that interferes with the ability to independently partake in everyday activities. 6 Dementia is a progressive and life-limiting condition. 7, 8 Many people with dementia live with other chronic conditions. 9 Compared to cognitively intact people of the same age, people with dementia live with just as many if not more chronic conditions, such as diabetes, heart disease and respiratory conditions. [10] [11] [12] The extent of chronic conditions experienced by people with dementia may be underestimated, as it can be a challenge to identify other conditions when they cannot reliably report signs and symptoms. 13, 14 Both health professionals and people with dementia often perceive one condition to take precedence over the others rather than considering all conditions equally. 15, 16 Chronic health conditions can affect the manifestation and progression of dementia. 17 Medications used to delay cognitive decline or the behavioural and psychological symptoms of dementia may negatively impact on the control of comorbidities. [18] [19] [20] An example is the introduction of anticholinesterase inhibitors leading to deteriorating bladder symptoms or increasing gastrointestinal symptoms. 19, 21 People with dementia may be more sensitive to medication side effects, although they may not be able to reliably report them. 22, 23 The common co-existence of dementia with other chronic conditions poses a challenge for health professionals to optimise medication use. 4 Limited evidence exists to guide the challenges of managing other chronic conditions in the presence of dementia. [24] [25] [26] Research often focuses on whether the chronic condition alters the risk of developing dementia, [27] [28] [29] [30] [31] [32] or whether the chronic condition alters the progression of dementia. 33 Evidence suggests that some medications may cause the dementia signs and symptoms to deteriorate. [34] [35] [36] Medication management becomes more challenging as the dementia progresses, 4 and the care goals may change, meaning that optimal medication management in the mild phase of dementia is not the same as in the severe stages. 37 Optimal medication management for chronic conditions in people who also have dementia is not well documented. [24] [25] [26] Older people are under-represented in research, and this applies even more so to older people with dementia. 38 Evidence for medication use once dementia is established tends to focus on medication use for cognitive or psychological symptoms. 9, 39 This literature review aimed to review the efficacy of medications used to manage chronic conditions in people who also have a diagnosis of dementia. The secondary aim was to review drug utilisation patterns to gauge if a dementia diagnosis alters drug utilisation.
METHODS

Selection Criteria
Types of Participants
This review considered studies that included people with a diagnosis of dementia in conjunction with one or more comorbidities. Age and gender were not considered. Papers were included regardless of setting (e.g. hospital, residential care or community).
Types of Interventions
This review considered quantitative studies that investigated pharmacological interventions for chronic conditions (comorbidities) in people with dementia.
Pharmacological interventions (defined as medicines prescribed by a doctor to prevent or treat disease) could be compared to placebo, no comparator, and people without dementia or people with dementia continuing usual care. Medication use was defined as the use of specific medications, medication classes or therapeutic classes.
We excluded studies where the medication use was intended to treat the dementia or symptoms of the dementia such as behavioural and psychological symptoms of dementia.
Outcome Measures
The primary outcome measure for this review was clinically-relevant health outcomes and quality of life measured with any standardised tool. Clinically-relevant health outcomes were defined as an outcome that the person would be aware of such as falls, fractures and events leading to hospital admissions. Clinically-relevant health outcomes included surrogate end-points that are commonly measured in practice and reported to the patient (e.g. blood pressure and blood sugar). Reported adverse drug events were considered.
The secondary outcome was to assess drug utilisation patterns for comorbidities in people with dementia. Drug utilisation was defined as reported patient use. Drug utilisation was also considered to include prescribing, dispensing or charting a medication for use. We were interested in drug utilisation as we wanted to investigate if there is any association between dementia and altered patterns of medication use in practice.
Specific medications, medication classes or therapeutic classes had to be reported using an unambiguous therapeutic or pharmacological class or individual medication. We did not place limits on the drug classification system used.
We excluded studies where the outcomes were only cognitive or psychological health outcomes and studies that reported the risk or rate of developing dementia. We excluded studies where the outcome reported was only the number of medications used or the prevalence of potentially inappropriate medications.
Types of Studies
Quantitative studies that used experimental and observational methods were considered for inclusion. Experimental study designs included in this review were randomised controlled trials (RCTs) or non-randomised controlled trials. The observational studies had to include a concurrent control group, such as cohort studies, cross-sectional studies and case-control studies. No limitation was placed on the length of follow-up.
Search Strategy
The search strategy aimed to identify published studies by searching the Ovid (MEDLINE and EMBASE) from commencement to March 2016, and updated in September 2016. The MEDLINE search strategy is presented in Table 1 . Reference lists of included studies were scanned for relevant studies.
Data Collection and Analysis
Selection of Studies
Electronic search results were downloaded and imported into Endnote X7.7 bibliographic software. 40 Duplicates were removed where possible. Three researchers (XH, VC, SK) independently screened the titles, then the abstracts of all records retrieved. All articles that appeared to meet the selection criteria from the title and abstract were retrieved and considered as full-text articles. Articles that could not be adequately assessed from the information given in the title and abstract were also considered as full text. Three researchers (XH, VC, SK) then independently assessed the full-text articles to deem them eligible or ineligible for inclusion. A fourth researcher (AP) acted as a moderator and repeated the screening process. Discrepancies were resolved by discussion. The reference lists of identified papers were scanned for relevant studies.
Data Extraction and Management
Three researchers equally divided eligible papers and independently extracted details. The information extracted from each paper was: study design and methodology, sample size, setting, follow-up duration, participant gender and age, inclusion and exclusion criteria, comorbidity targeted, intervention dates, reported outcomes, relevant outcome data and, where relevant, the intervention details. Any additional material considered to be relevant to the review was also extracted at the researcher's discretion.
Assessment of Risk of Bias
Two reviewers critically analysed and assessed each paper for risk of bias. The Cochrane Collaboration 'Risk of Bias' tool was used for RCTs. 41, 42 The non-randomised studies were assessed with the modified Cochrane Collaboration risk of bias tool and the Newcastle-Ottawa tool as a recommendation from the Cochrane Handbook. 42 The modified Cochrane Collaboration risk of bias tool had an additional item to assess the risk of bias from confounding. Subsequently, each study was assigned either a high, moderate or low risk.
Of the papers each individual critically analysed, an assessed risk of bias was also made.
Data Synthesis
The data were grouped according to the reported comorbidity. Where data were available for both groups, the dichotomous outcomes were reported as odds ratios (ORs), and continuous outcomes were reported as mean difference. Where the data were reported as ORs and mean difference with the measure of variance, we reported the values as given in the original paper.
Where the data were available but not reported in this format, the authors used Review Manager (RevMan) 5.3 software 43 to calculate the ORs and mean difference with the 95% confidence interval (CI) for the data. Data were not pooled to undertake a meta-analysis. 
RESULTS
Results of the Search
The initial search returned 2246 studies and a further 49 papers were identified by screening the reference lists of articles considered for inclusion ( Figure 1) . A total of 25 full-text papers were retrieved for further consideration. Of these, six papers met the inclusion criteria.
Included Studies
The review included six studies with a total of 51 696 participants, who were 78% female with a weighted mean age across all studies of 81.1 AE 2.0 years. The study characteristics are presented in Table 2 . 
Risk of Bias
The assessment of risk of bias for five out of six included studies incorporated a measure of confounding and assessment with both the Cochrane Collaboration and the Newcastle-Ottawa risk of bias tools as they were observational studies rather than experimental studies (Figure 2) . 41 Using the Cochrane tool, the risk of bias was assessed as high in more than half of the studies across four domains. [44] [45] [46] [47] [48] Using the NewcastleOttawa risk of bias tool, the risk of bias was assessed as low for at least half the studies in six of the eight domains.
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Outcomes
The six studies reported five distinct outcomes. Clinically-relevant health outcomes were reported in one study that reported bisphosphonate treatment for osteoporosis in people with moderate dementia. 49 Clinical parameters were reported in one study, namely blood pressure, haemoglobin A1C (HBA 1C ), blood glucose and cholesterol. 48 Drug utilisation patterns were evaluated in five studies. [44] [45] [46] [47] [48] These are described in more detail below.
Quality of Life
No studies reported the effect of treating physical or psychiatric comorbidities on quality of life in people with dementia in a manner where it could be determined that the participant had a diagnosis of both dementia and the comorbidity.
Health Outcomes by Comorbidity
Osteoporosis Treatment: One experimental study investigated medication use for people with moderate dementia and osteoporosis. 49 Risedronate 2.5 mg daily compared to placebo reduced the risk of a non-vertebral fracture (OR = 0.27, 95% CI 0.12-0.61, participants = 500, studies = 1) including hip fracture (OR = 0.25, 95% CI 0.09-0.68, participants = 500, studies = 1). 49 The risk of adverse drug effects was not increased in the risedronate group compared to placebo (OR = 2.02, 95% CI 0. 50-8.19 , participants = 500, studies = 1).
Cardiovascular and Diabetic Treatment Targets: One case-control study investigated medication use for diabetes, hypertension and hyperlipidaemia across people with dementia at any stage compared to age-matched peers without dementia. 48 This study reported blood pressure, blood glucose, HbA 1C and cholesterol treatment targets (Table 3 ). This study suggests that blood pressure may have been lower in people with dementia than without, but that serum cholesterol, blood glucose and HBA 1C is treated to similar targets in people with and without dementia.
Drug Utilisation Patterns for Comorbidities
Five studies reported drug utilisation, which are presented in Table 4 . [44] [45] [46] [47] [48] Compared to people without dementia, people with dementia were less likely to be dispensed osteoporosis medication. Oral anticoagulation and antiplatelet agents were more likely to be prescribed to people with dementia who also had atrial fibrillation compared to those without atrial fibrillation.
Other drug utilisation patterns were not found to be different.
DISCUSSION
We identified six papers, involving a total of 51 696 participants that addressed medication use for people with dementia to manage specific comorbidities, namely osteoporosis, diabetes, depression and cardiovascular disease. [44] [45] [46] [47] [48] [49] We found little evidence to guide medication use to manage comorbidities with only one paper that reported clinically-relevant health outcomes. 49 The one experimental study found treatment with a bisphosphonate compared to placebo reduced fractures in people with moderate dementia and osteoporosis. However, the majority of the studies evaluated drug utilisation patterns rather than health outcomes. [44] [45] [46] [47] [48] Drug utilisation patterns for people with dementia were evaluated in these studies using treatment targets and standards based on existing evidence in people without dementia. Osteoporosis increases the risk of fractures and the consequences of fractures include an increased morbidity and premature mortality, but can also result in deteriorating quality of life and substantial pain. Current treatment for all people with osteoporosis is to provide treatment for a finite duration to reduce the risk of fracture. [50] [51] [52] Bisphosphonates are documented to have an onset time for benefit to reduce fractures; bisphosphonates have been shown to have a reduction in fracture incidence after 2 years. 53 The experimental study included in this literature review found that even in moderate dementia, mobile people continued to receive benefits from bisphosphonate treatment. Bisphosphonate treatment compared to placebo resulted in fewer fractures. 49 This evidence supports the benefit from bisphosphonate treatment to ambulant people with dementia. However, people with osteoporosis were less likely to be dispensed bisphosphonate treatment if they had a diagnosis of dementia compared to people without dementia. 44 The drug utilisation patterns reported in these observational studies confirmed that comorbidities for people with dementia are managed pharmacologically. [44] [45] [46] [47] [48] 54 Drug utilisation patterns and treatment targets for chronic comorbidities such as cardiovascular disease and diabetes appear to be similar for people with and without dementia until the severe stage. 44, 46, 48 For example, treatment targets for blood pressure, cholesterol and diabetes were shown to be similar for people with and without dementia. 48 Recent consensus statements suggested that the targets should be relaxed as dementia progresses. 55 The observed treatment targets suggest medication use could be improved by considering individual patient preferences and care goals. 55 On the other hand, drug utilisation patterns of anticoagulants and antiplatelet agents for people with atrial fibrillation were similar for people with and without dementia in the moderate stage. 44 This is consistent with recent consensus that anticoagulant and antiplatelet agents should continue through into moderate dementia. 55 It was only the presence of a caregiver in the home that altered medication use patterns, which suggests that social and practical considerations may affect drug utilisation patterns more than a dementia diagnosis. 44 It is less clear whether these medications are improving health outcomes or quality of life. Comorbidities do interact with the dementia to either cause challenges in medication management or a suggested accelerated deterioration or exacerbation of at least one disease state. 33, 56 This interaction may be related to disease-disease interaction or it may be related to the impact on the dementia of managing other chronic comorbidities. 57 There are suggestions that chronic conditions such as cardiovascular diseases can affect people with dementia more than people without dementia. 16 We have little evidence to suggest whether managing these comorbidities with medications can cause improved health outcomes or quality of life for people with dementia. Further, we do not have information on whether people with dementia have time to benefit from medications intended to prevent future serious events or disease progression.
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The literature review revealed only one study that provided information on medication use to alter health outcomes, namely that medications to treat osteoporosis are beneficial for people with moderate dementia. 49 The other five studies suggested that current drug utilisation patterns and targets are similar for people with and without dementia. [44] [45] [46] [47] [48] The recent publication of consensus-based agreement on the approach to manage comorbidities and this literature review suggest that the consensus-based agreement represents our current best evidence. 55 There is a need for future research to evaluate the effect on health outcomes and quality of life in people with dementia. Future research needs to apply clinically-relevant outcomes without the use of surrogate end-points in the context of a life-limiting condition. Several limitations to this review are worth noting. Although the search strategy was comprehensive, only two databases were searched. Second, we introduced language bias by only searching in the English language. Third, the studies were limited in both number and quality with almost all being observational designs. In most cases, the studies included only reported on medication usage rather than medication appropriateness. We were looking for clinically-relevant outcomes and quality of life as those are important to consumers who live with multi-morbidity.
There is currently insufficient evidence to guide medication management for people with dementia to ensure good clinical outcomes and quality of life. Many included studies had lower levels of evidence and all but one focused on drug utilisation patterns rather than the clinically-relevant outcomes. Comorbidities for people with dementia appear to be managed pharmacologically until the severe stages of disease. Estimates of probable dementia prevalence from population-based 
